ACM
MDGL icon

Accent Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Accent Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Sell
31
-39
-56% -$20K 0.01% 169
2026
Q1 		$36.6K Sell
70
-24
-26% -$11.5K 0.02% 121
2025
Q4 		$54.7K Buy
94
+37
+65% +$18.9K 0.02% 86
2025
Q3 		$26.1K Sell
57
-37
-39% -$13.8K 0.01% 126
2025
Q2 		$28.4K Buy
94
+19
+25% +$5.66K 0.01% 135
2025
Q1 		$24.8K Buy
+75
New +$24.6K 0.01% 146

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Accent Capital Management's MDGL Position: Q2 2026 in Review

Accent Capital Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 56% in Q2 2026, selling an estimated $20K and leaving 31 shares worth $16.6K. The position accounts for 0.01% of the portfolio, ranked #169.

Accent Capital Management first reported a position in MDGL in Q1 2025 and has held it in 6 quarters since. The position peaked at $54.7K in Q4 2025. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Accent Capital Management held 31 shares of Madrigal Pharmaceuticals worth $16.6K as of Q2 2026.
  • Accent Capital Management sold 39 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $20K.
  • Madrigal Pharmaceuticals made up 0.01% of Accent Capital Management's portfolio in Q2 2026, its #169 holding.
  • Accent Capital Management first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Accent Capital Management's Madrigal Pharmaceuticals position peaked at $54.7K in Q4 2025.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.